Groupe la Francaise Acquires Shares of 775,382 Organon & Co. $OGN

Key Points

• Groupe la Francaise acquired 775,382 Organon & Co. shares in the second quarter, valued at approximately $10.5 million and representing about 0.30% of the company. Institutional investors collectively own 77.43% of Organon’s stock.
• Organon’s shares opened at $13.78, near their 12-month high, with a market capitalization of $3.62 billion. The company also announced a quarterly dividend of $0.02 per share, equal to a 0.6% annualized yield.
• Analyst sentiment remains cautious: Organon has a consensus rating of “Reduce” from five Hold and two Sell ratings, with an average price target of $11.40.

Groupe la Francaise acquired a new stake in shares of Organon & Co. (NYSE:OGN - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 775,382 shares of the company's stock, valued at approximately $10,499,000. Groupe la Francaise owned approximately 0.30% of Organon & Co. as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the company. Private Management Group Inc. raised its holdings in shares of Organon & Co. by 38.3% during the 4th quarter. Private Management Group Inc. now owns 4,347,073 shares of the company's stock worth $31,169,000 after acquiring an additional 1,204,979 shares in the last quarter. California State Teachers Retirement System increased its holdings in shares of Organon & Co. by 34.8% in the 1st quarter. California State Teachers Retirement System now owns 327,075 shares of the company's stock worth $1,959,000 after buying an additional 84,497 shares during the last quarter. UBS Group AG raised its position in Organon & Co. by 55.2% during the fourth quarter. UBS Group AG now owns 4,295,002 shares of the company's stock valued at $30,795,000 after purchasing an additional 1,527,492 shares during the period. Orographic Financial Advisors LLC purchased a new stake in Organon & Co. during the first quarter valued at approximately $1,522,000. Finally, Sei Investments Co. lifted its stake in shares of Organon & Co. by 82.0% in the 1st quarter. Sei Investments Co. now owns 190,057 shares of the company's stock valued at $1,139,000 after purchasing an additional 85,657 shares during the last quarter. 77.43% of the stock is owned by institutional investors.

Organon & Co. Price Performance

OGN stock opened at $13.78 on Monday. The stock has a market cap of $3.62 billion, a PE ratio of 17.90, a P/E/G ratio of 1.28 and a beta of 1.52. Organon & Co. has a 12 month low of $5.69 and a 12 month high of $13.78. The company has a 50-day moving average price of $13.61 and a 200 day moving average price of $11.34. The company has a current ratio of 1.95, a quick ratio of 1.44 and a debt-to-equity ratio of 8.43.

Organon & Co. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be given a dividend of $0.02 per share. This represents a $0.08 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Organon & Co.'s payout ratio is 10.39%.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded Organon & Co. from a "hold (c)" rating to a "hold (c-)" rating in a research report on Monday, August 3rd. Five research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Organon & Co. currently has a consensus rating of "Reduce" and a consensus target price of $11.40.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.